Navigation Links
Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures
Date:3/24/2010

The occurrence of an unusual type of fracture of the femur, or the thigh bone, is very low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according to a new study led by a team of UCSF epidemiologists.

San Francisco, CA (Vocus) March 24, 2010 -- The occurrence of an unusual type of fracture of the femur, or the thigh bone, is very low in patients with osteoporosis, including those treated with the drug family known as bisphosphonates, according to a new study led by a team of UCSF epidemiologists.

While these unusual femur fractures have been reported in case series studies in patients, particularly in those taking bisphosphonates, this UCSF study is the first to examine their occurrence systematically using data from randomized trials, the most rigorous type of study design. The study combined data from three bisphosphonate trials that involved more than 14,000 patients.

The new findings contextualize reports from the American Academy of Orthopaedic Surgeons and news stories on bisphosphonates and femur fractures that have appeared in recent weeks, according to study principal investigator Dennis Black, PhD, UCSF professor of epidemiology and biostatistics.

The study shows that these fractures remain rare even in a population of women who have been taking the drugs for as long as 10 years, said Black, who specializes in osteoporosis treatment and prevention in post menopausal women. While the risk was not significantly increased among the women taking bisphosphonates compared to placebo, the number of events was too low to definitely rule out a relationship, he said.

The study is scheduled to appear online on March 24, 2010 at NEJM.org and will be published in an upcoming print issue of The New England Journal of Medicine.

Bisphosphonates (marketed as Fosamax, Actonel, Boniva, and Reclast) are the most commonly used treatment for postmenopausal osteoporosis. They belong to the class of anti-restorative drugs that act by slowing bone degradation, or desorption, and thereby increase bone density and reduce the risk of fractures.

The UCSF researchers focused on fractures in the shaft of the femur. Breaks in this region are much less common than hip fractures that occur closer to the top of the bone and are most commonly associated with trauma.

Case reports in recent years have reported femur breaks in patients taking bisphosphonates, occurring with little trauma and having an atypical appearance on x-rays. However, there has been no rigorous large scale study to determine a relationship.

The UCSF study is now the first to do this, using data from the records of a total of 14,195 women who participated in three previous controlled, randomized bisphosphonate trials. The women ranged in age from 65 to 85, and the studies followed them for up to 10 years. There was a total of over 51,000 years of follow up in the three studies combined.

Black's team reevaluated the records for femur fractures in the three trials: two that studied use of oral alendronate (a placebo-controlled phase III trial and randomized extension to 10 years treatment) and one on the use of zoledronic acid (a placebo-controlled trial with the drug infused annually). The trials used similar protocols for original collection and classification of fractures.

In their analysis, the UCSF researchers considered the location of the fracture and compared occurrence in patients who received bisphosphonates versus those who received placeboes.

They reviewed records of 283 hip or femur fractures and found a total of 12 fractures in 10 women that were classified as subtrochanteric/diasphyseal femur fractures. They found no significant relationship between bisphosphonate use and increase in risk for these fractures, although the relatively small numbers preclude definitive conclusions, according to Black.

"We found that fractures are very rare, less then 3 per 10,000 years of treatment, even in populations treated for a very long time,” Black said. "The trade-off between the risk of this type of fracture and the overall benefit of these medications to osteoporotic patients is striking. The public needs to understand the rare incidence of atypical femoral fractures and the high risk of debilitating fractures in patients with osteoporosis if left untreated. These are important risks and benefits for patients to weigh with their doctors.”

He also recommends that patients taking bisphosphonates long term consult their doctors if they experience pain in their thighs, suggesting "It may be time to consider a drug holiday.”

Black and his team recommend future studies to assess additional risk factors that could identify a subgroup of patients who might be more vulnerable to rare subtrochanteric/diasphyseal femur fractures.

The UCSF researchers say that an increase of risk might be focused on patients who take other medications such as corticosteroids or other medications that treat osteoporosis such as hormone replacement therapy. They suggest further research include observational studies from population-based registries or healthcare databases that retain radiographs as useful alternatives.

The three trials that provided data for the UCSF study are the Fracture Intervention Trial, known as FIT; the FIT Long-Term Extension Trial, known as FLEX; and the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial, known as HORIZON-PFT.

An estimated 10 million Americans have osteoporosis and 34 million more are prone because of low bone density. Patients with significant osteoporosis are at high risk of debilitating fractures: the disease is responsible for more than 1.5 million annually, according to the National Institutes of Health. Only half of people who have lived independently before a hip fracture are able to do so one year later, said Black.

In addition to Black, UCSF study co-authors are Michael P. Kelly, MD; Harry K. Genant, MD (Emeritus); Lisa Palermo, PhD; and Douglas C. Bauer, MD.

Other co-authors are Richard Eastell, MD, University of Sheffield, U.K.; Christina Bucci-Rechtweg, MD, Novartis Pharmaceuticals; Jane Cauley, PhD, University of Pittsburg; Ping Chung Leung, MD, University of Hong Kong; and Steven Boonen, MD, PhD, Katholieke Universiteit Leuven, Belgium; and Arthur Santora, MD, and Anne de Papp, MD, of Merck Research Laboratories, Rahway, NJ.

The UCSF study was supported by research contracts from Novartis and Merck.

UCSF is a leading university that advances health worldwide by conducting advanced biomedical research, educating graduate students in the life sciences and health professions, and providing complex patient care.

Contact:
Nicole Pagano
(415) 476-2557
www.ucsf.edu

# # #

Read the full story at http://www.prweb.com/releases/UCSF/osteoporosis-treatments/prweb3776384.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Say Cheese! New Study Confirms Health Benefits of Pecorino Romano Cheese
2. Study evaluates costs and benefits associated with new colon cancer therapies
3. Study evaluates costs and benefits of new chemotherapy drugs
4. Health Benefits Direct Announces Extension of Expiration of Rights Offering to March 26, 2010
5. New study questions benefits of elective removal of ovaries during hysterectomy
6. Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis
7. LG Electronics Expands Benefits of Healthcare HDTVs With New Compliance Ratings at HIMSS 2010
8. Greenway Medical Technologies Advances Patient-Provider Benefits
9. DSM Personalized Nutrition Webinar Explores Benefits of Nutrition for Employee Health
10. Surgeon General with Microsoft HealthVault Expands Consumer Benefits for the My Family Health Portrait Offering
11. Freedom Healthnet Affirms Affordable Private Health Insurance Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Benefits of Osteoporosis Treatments Outweigh Possible Risk of Rare Femoral Fractures
(Date:4/28/2016)... Calif. (PRWEB) , ... April 28, 2016 , ... ... manufacturer specializing in the development of miniature microphones and headsets announced today that ... headset design method of integrating in-earphones into a structure. This innovative design creates ...
(Date:4/28/2016)... ... April 28, 2016 , ... Accreditation Commission ... Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty Pharmacy Accreditation with Distinction ... an accreditation distinction. ACHC provides a wide range of pharmacy accreditation services that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Starting today, ... the mail from USA Medical Prescription Assistance Program. They are customized to reflect ... mailed package will include a ready-to-use, state-themed card and, in the near future, ...
(Date:4/28/2016)... , ... April 28, 2016 , ... For the 10,000 ... getting smarter about an important part of overall well-being: mental health. Now, a new ... to promote healthy aging and “cognitive vitality,” which can include everything from honing your ...
(Date:4/28/2016)... , ... April 28, 2016 ... ... invitation to those affected by a health insurance co-operative bankruptcy to receive ... process, individuals can receive over 1,500 FDA-approved prescription medications from over 180 ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... April 27, 2016 Transparency Market ... Devices Market - Global Industry Analysis, Size, Share, Growth, ... report, the global skincare devices market was valued at ... expand at a CAGR of 10.1% from 2015 to ... Browse the full Skincare Devices Market (Treatment Device - ...
(Date:4/27/2016)... , April 27, 2016  Bayer Animal ... a senior from the University of Florida College ... the Bayer Excellence in Communication Award (BECA). Brittany ... which were awarded a total of $70,000 in ... last four years, Bayer has provided a total ...
(Date:4/27/2016)... YORK , April 27, 2016 ... OASM ), a developer of a new generation ... announced positive overall survival results for Paclical/Apealea in ... of 789 patients with epithelial ovarian cancer. These ... groups: Paclical/Apealea in combination with carboplatin versus Taxol ...
Breaking Medicine Technology: